Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Valganciclovir (marketed as Valcyte) Information

Valcyte (valganciclovir) is indicated for:

Adult Patients

  • Treatment of Cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
  • Prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk.

Pediatric Patients

  • Prevention of CMV disease in kidney or heart transplant patients at high risk.

To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.

Contact FDA

1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

Page Last Updated: 03/25/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English